Increased insulin clearance in peroxisome proliferator-activated receptor γ2 pro12Ala

Metabolism: Clinical and Experimental

Volumn 52, Issue 6, 2003, Pages 778-783

  Tschritter, Otto ^a   Fritsche, Andreas ^a   Stefan, Norbert ^a   Haap, Michael ^a   Thamer, Claus ^a   Bachmann, Oliver ^a   Dahl, Dominik ^a   Maerker, Elke ^a   Teigeler, Anna ^a   Machicao, Fausto ^a   Häring, Hans ^a   Stumvoll, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; C PEPTIDE; FATTY ACID; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; UNCLASSIFIED DRUG; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ADULT; ALLELE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN INFUSION; INSULIN SENSITIVITY; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; STEADY STATE; GENETICS; GLUCOSE TOLERANCE TEST; METABOLISM; PHYSIOLOGY;

ADULT; ALANINE; ALLELES; C-PEPTIDE; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0042814753     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00071-4     Document Type: Article

References (41)

1. Yen CJ, Beamer BA, Negri C, et al: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: Identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241:270-274, 1997
2. Altshuler D, Hirschhorn JN, Klannemark M, et al: The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80, 2000
3. Mori H, Ikegami H, Kawaguchi Y, et al: The Pro12 → Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50:891-894, 2001
4. Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999
5. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 20:649-688, 1999
6. Beamer BA, Yen CJ, Andersen RE, et al: Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47:1806-1808, 1998
7. Deeb SS, Fajas L, Nemoto M, et al: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287, 1998
8. Koch M, Rett K, Maerker E, et al: The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42:758-762, 1999
9. Meirhaeghe A, Fajas L, Helbecque N, et al: A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7:435-440, 1998
10. Valve R, Sivenius K, Miettinen R, et al: Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84:3708-3712, 1999
11. Mori Y, Kim Motoyama H, Katakura T, et al: Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 251:195-198, 1998
12. Jacob S, Stumvoll M, Becker R, et al: The PPARgamma2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 32:413-416, 2000
13. Poy MN, Yang Y, Rezaei K, et al: CEACAM1 regulates insulin clearance in liver. Nat Genet 30:270-276, 2002
14. Fritsche A, Madaus A, Tschritter O, et al: [Polymorphism of pro12Ala in peroxisome proliferator activated receptor gamma2 (PPAgamma2): Beta cell function and insulin sensitivity]. Dtsch Med Wochenschr 126:580-584, 2001
15. Stefan N, Fritsche A, Häring H, et al: Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of peroxisome-proliferator-activated receptor gamma2 gene. Diabetes 50:1143-1148, 2001
16. Stumvoll M, Wahl HG, Löblein K, et al: The Pro12Ala polymorphism in the peroxisome proliferator activated receptor g2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 50:876-881, 2001
17. Stumvoll M, Stefan N, Fritsche A, et al: Interaction effect between common polymorphisms in PPARgamma2 (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity. J Mol Med 80:33-38, 2002
18. World Health Organization Expert Committee: Second Report on Diabetes Mellitus Geneva, Switzerland, Technical Report Series, 1980, pp No. 646-No. 641
19. Fritsche A, Stefan N, Hardt E, et al: A novel hyperglycemic clamp for characterization of islet function in humans: Assessment of three different secretagogues, maximal insulin response and reproducibility. Eur J Clin Invest 30:411-418, 2000
20. Iozzo P, Beck-Nielsen H, Laakso M, et al: Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab 84:863-868, 1999
21. Mittelman SD, Van Citters GW, Kim SP, et al: Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes 49:2116-2125, 2000
22. Michael MD, Kulkarni RN, Postic C, et al: Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6:87-97, 2000
23. Bavenholm PN, Pigon J, Ostenson CG, et al: Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes 50:1449-1454, 2001
24. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
25. Svedberg J, Bjorntorp P, Smith U, et al: Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes 39:570-574, 1990
26. Svedberg J, Stromblad G, Wirth A, et al: Fatty acids in the portal vein of the rat regulate hepatic insulin clearance. J Clin Invest 88:2054-2058, 1991
27. Wiesenthal SR, Sandhu H, McCall RH, et al: Free fatty acids impair hepatic insulin extraction in vivo. Diabetes 48:766-774, 1999
28. Campbell PJ, Carlson MG, Nurjhan N: Fat metabolism in human obesity. Am J Physiol 266:E600-E605, 1994
29. Jones CN, Pei D, Staris P, et al: Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 82:1834-1838, 1997
30. Peiris AN, Mueller RA, Smith GA, et al: Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 78:1648-1657, 1986
31. Rossell R, Gomis R, Casamitjana R, et al: Reduced hepatic insulin extraction in obesity: Relationship with plasma insulin levels. J Clin Endocrinol Metab 56:608-611, 1983
32. Bergman RN: Non-esterified fatty acids and the liver: Why is insulin secreted into the portal vein? Diabetologia 43:946-952, 2000
33. Mittelman SD, Bergman RN: Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 279:E630-E637, 2000
34. Rebrin K, Steil GM, Getty L, et al: Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 44:1038-1045, 1995
35. Chen X, Iqbal N, Boden G: The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103:365-372, 1999
36. Berg AH, Combs TP, Du X, et al: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
37. Combs TP, Berg AH, Obici S, et al: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881, 2001
38. Combs TP, Wagner JA, Berger J, et al: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: A potential mechanism of insulin sensitization. Endocrinology 143:998-1007, 2002
39. Maeda N, Takahashi M, Funahashi T, et al: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
40. Polonsky K, Frank B, Pugh W, et al: The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes 35:379-386, 1986
41. Polonsky KS, Rubenstein AH: C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33:486-494, 1984